Nuvation Bio (NUVB) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
10 Apr, 2026Executive summary
Annual Meeting scheduled for May 21, 2026, via live webcast, with record date of March 25, 2026.
Stockholders will vote on director elections, ratification of KPMG LLP as auditor, and an advisory say-on-pay vote.
Voting instructions provided for online, phone, and mail participation; quorum requirements detailed.
Board recommends voting in favor of all proposals.
Voting matters and shareholder proposals
Three proposals: election of three directors, ratification of KPMG LLP as auditor for 2026, and advisory approval of executive compensation.
Class A and Class B stockholders vote together for two directors; Class B stockholders vote separately for one director.
Stockholder proposals for the 2027 meeting must be submitted by December 11, 2026, for inclusion in proxy materials.
Board of directors and corporate governance
Board consists of seven members, divided into three classes with staggered three-year terms.
Majority of directors are independent per NYSE standards; Dr. Hung serves as Board Chair, Mr. Bazemore as Lead Independent Director.
Board committees: audit, compensation, and nominating/corporate governance, each with defined charters and responsibilities.
Board and committees met regularly in 2025, with all directors attending at least 75% of meetings.
Latest events from Nuvation Bio
- IBTROZI’s global approvals and strong efficacy drive growth, with safusidenib advancing in pivotal trials.NUVB
Corporate presentation16 Jun 2026 - IBTROZI's superior efficacy and CNS benefits drive ROS1 market leadership; pipeline and financials remain strong.NUVB
Jefferies Global Healthcare Conference 20263 Jun 2026 - IBTROZI's first-line growth accelerates as pipeline assets advance in high-need glioma settings.NUVB
7th Annual Oncology Innovation Summit: Insights for ASCO & EHA28 May 2026 - IBTROZI and safusidenib drive growth with best-in-class data and major upcoming clinical catalysts.NUVB
H.C. Wainwright 4th Annual BioConnect Investor Conference22 May 2026 - All proposals passed, including director elections and auditor ratification, with strong quorum.NUVB
AGM 202621 May 2026 - First-line growth, new testing mandates, and pipeline advances position for multibillion-dollar markets.NUVB
RBC Capital Markets Global Healthcare Conference 202620 May 2026 - ZUSDURI sees rapid adoption and durable results, fueling growth and pipeline expansion.NUVB
Bank of America Global Healthcare Conference 202613 May 2026 - Ibtrozi's first-line growth and Eisai deal drive strong Q1 2026 results and global expansion.NUVB
Q1 202610 May 2026 - IBTROZI drives strong growth in ROS1+ NSCLC as safusidenib and DDCs advance in oncology.NUVB
Investor presentation4 May 2026 - First-line patient growth and robust pipeline drive strong outlook and international expansion.NUVB
TD Cowen 46th Annual Health Care Conference29 Apr 2026